Literature DB >> 12895319

[Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report].

Xing-wang Li1, Rong-meng Jiang, Jia-zhen Guo.   

Abstract

OBJECTIVE: To discuss the effect of glucocorticoid (methylprednisolone) on severe acute respiratory syndrome (SARS).
METHODS: Thirty SARS patients were treated at our hospital for over 3 weeks since March to May 2003. The course and dosage of glucocorticoid, counts of CD(4)(+), CD(8)(+) and CD(3)(+), electrolytes, blood routine, and sera albumin before and after the treatment were analysed.
RESULTS: Before treatment by methylprednisolone, the counts of CD(4)(+), CD(8)(+) and CD(3)(+) of 27 SARS patients were (401 +/- 203), (340 +/- 187), (756 +/- 383) cells/ microl. Twenty-nine of the 30 SARS patients were treated by methylprednisolone. The dosage for 24 patients was 80 - 160 mg/d with the largest being 1,000 mg/d before admission to the hospital. The count of WBC was increased after treatment (P < 0.01). No obvious effect was observed on the potassium, sodium and chlorine of blood (P > 0.05). Glucocorticoid increased the level of blood glucose (P = 0.01), decreased the level of sera albumin (P < 0.01), and its large dosage decreased the counts of CD(4)(+), CD(8)(+) and CD(3)(+). Three severe patients had secondary infection after administration of a large dose of glucocorticoid.
CONCLUSIONS: In the early stage of the disease, the counts of CD(4)(+), CD(8)(+) and CD(3)(+) of SARS patients may reduce markedly indicating the immunity is suppressed. A large dose of glucocorticoid may aggravate the suppression and make the body in an active metabolic state (the increase of blood glucose and the decrease of sera albumin). Thus the disease is aggravated and patients are likely to suffer from severe secondary infection. Indications for use of glucocorticoid must strictly controlled and its large dosage is improper.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895319

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  11 in total

1.  COVID-19 managed with early non-invasive ventilation and a bundle pharmacotherapy: A case report.

Authors:  Mian Peng; Di Ren; Xue-Yan Liu; Jin-Xiu Li; Rong-Lin Chen; Bao-Jun Yu; Yong-Feng Liu; Xi Meng; Yan-Si Lyu
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

2.  Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome.

Authors:  Xinsheng Zhang; Konstantin Alekseev; Kwonil Jung; Anastasia Vlasova; Nagesh Hadya; Linda J Saif
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

3.  Application of albumin/globulin ratio in elderly patients with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Jinqiu Qin; Yuanyuan Qin; Yangyang Wu; Aiqiu Wei; Meiling Luo; Lin Liao; Faquan Lin
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

4.  Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study.

Authors:  Joost Wauters; Ingrid Baar; Philippe Meersseman; Wouter Meersseman; Karolien Dams; Rudi De Paep; Katrien Lagrou; Alexander Wilmer; Philippe Jorens; Greet Hermans
Journal:  Intensive Care Med       Date:  2012-08-16       Impact factor: 17.440

5.  Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience.

Authors:  Rong-Chang Chen; Xiao-Ping Tang; Shou-Yong Tan; Bi-Ling Liang; Zhuo-Yue Wan; Ji-Qian Fang; Nanshan Zhong
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

6.  Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection.

Authors:  I Martin-Loeches; T Lisboa; A Rhodes; R P Moreno; E Silva; C Sprung; J D Chiche; D Barahona; M Villabon; C Balasini; R M Pearse; R Matos; J Rello
Journal:  Intensive Care Med       Date:  2010-11-24       Impact factor: 17.440

Review 7.  Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with SARS-Cov-2 Infection.

Authors:  Graciela Cárdenas; Diana Torres-García; Jacquelynne Cervantes-Torres; Sergio Rosales-Mendoza; Agnes Fleury; Gladis Fragoso; Juan Pedro Laclette; Edda Sciutto
Journal:  Arch Med Res       Date:  2020-10-26       Impact factor: 2.235

8.  Serum surfactant protein D (SP-D) is a prognostic marker of poor outcome in patients with A/H1N1 virus infection.

Authors:  Carlos Delgado; Edgar Krötzsch; Luis A Jiménez-Alvarez; Gustavo Ramírez-Martínez; Jose E Márquez-García; Alfredo Cruz-Lagunas; Juan Morán; Cármen Hernández; Patricia Sierra-Vargas; Federico Avila-Moreno; Carina Becerril; Martha Montaño; José L Bañales-Méndez; Joaquín Zúñiga; Ivette Buendía-Roldán
Journal:  Lung       Date:  2014-12-24       Impact factor: 2.584

9.  The SARS epidemic in mainland China: bringing together all epidemiological data.

Authors:  Dan Feng; Sake J de Vlas; Li-Qun Fang; Xiao-Na Han; Wen-Juan Zhao; Shen Sheng; Hong Yang; Zhong-Wei Jia; Jan Hendrik Richardus; Wu-Chun Cao
Journal:  Trop Med Int Health       Date:  2009-06-05       Impact factor: 2.622

10.  Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong.

Authors:  Loretta Yin-Chun Yam; Arthur Chun-Wing Lau; Florence Yuk-Lin Lai; Edwina Shung; Jane Chan; Vivian Wong
Journal:  J Infect       Date:  2006-03-15       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.